Form 4: Rallybio Director Robert Hopfner Acquires Options in Lieu of Retainer Fees
SEC Form 4 Filing
Director Robert Lorne Hopfner acquired options to purchase 73,571 shares of Rallybio Corp common stock on January 2, 2025, in lieu of $51,500 in retainer fees.
Summary
- Robert Lorne Hopfner, a director of Rallybio Corp, acquired options to purchase 73,571 shares of common stock on January 2, 2025.
- The options were granted in lieu of $51,500 in retainer fees, under the company's 2021 Equity Incentive Plan.
- The exercise price of the options is $0.95.
- The options vest in 12 equal monthly installments throughout 2025, and expire on January 2, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The director's acceptance of options in lieu of cash suggests confidence in the company's future, and it helps the company conserve cash. However, it's a routine transaction.
Positives
- The acquisition of options by a director demonstrates confidence in the company's future prospects.
- Using equity in lieu of cash retainer fees preserves the company's cash resources.
Industry Context
Granting options to directors is a common practice in the biotech industry to align their interests with those of shareholders and conserve cash, especially for companies in the development stage like Rallybio.
Comparison to Industry Standards
- Many biotech companies, such as BioNTech and Moderna, use equity-based compensation for their directors and executives.
- The specific amount and vesting schedule of the options are typical for director compensation in similarly sized biotech firms.
- The use of equity in lieu of cash is a common strategy for companies focused on research and development to manage their cash flow effectively, similar to practices seen at companies like CRISPR Therapeutics.
Stakeholder Impact
- Shareholders may view the director's acceptance of options positively, as it aligns their interests with the company's success.
- The company benefits from conserving cash by issuing options instead of paying cash retainer fees.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the transaction: Robert Hopfner acquired options to purchase Rallybio Corp shares. |
| 01/02/2035 | Expiration date of the options. |
| 01/06/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.